Navigation Links
Nfocus Neuromedical Announces Acquisition of StarFire Medical
Date:3/6/2008

PALO ALTO, Calif., March 6 /PRNewswire/ -- Nfocus Neuromedical, Inc. announced today that it has completed the acquisition of StarFire Medical, Inc. StarFire Medical is a manufacturer of therapeutic implantable devices for interventional (minimally invasive) treatment of neurovascular disease.

The assets acquired include products such as the DSB (Detachable Silicone Balloon) and the NDSB (Non-Detachable Silicone Balloon), also known as the Endeavor Balloon Catheter, both of which have been cleared for marketing by the FDA and through CE marking in Europe. The DSB is a silicone balloon which is used to treat neurovascular fistulas and aneurysms through endovascular (less-invasive catheter) techniques. The DSB can be navigated to the site of pathology, inflated and detached to produce a permanent embolization for symptomatic carotid-cavernous fistulas and for aneurysm treatment through parent vessel occlusion. The NDSB is a soft silicone balloon attached to a very flexible microcatheter and is used for temporary and test occlusion during endovascular procedures.

The acquisition also included other neurovascular devices and Intellectual Property (IP) of StarFire. The remaining StarFire IP is focused on advanced intracranial aneurysm treatment devices that are in development.

"There has been strong physician interest in having access to these types of products in the United States," stated Martin S. Dieck, President and Chief Executive Officer of Nfocus Neuromedical. "The combination of StarFire's existing FDA-cleared devices and advanced aneurysm cover technology fits perfectly with the Nfocus product platform."

Hemorrhagic Stroke

Hemorrhagic stroke is a critical and often life-threatening event most frequently brought on by a rupturing aneurysm or other vascular malformation. In many cases, open surgery may not be ideal or even possible, but the alternative, current endovascular devices, may not provide permanent treatment. It is these critical and underserved patients and their physicians, the interventional neuroradiologist and neurointerventional surgeon, which Nfocus is committed to serve.

For more information about aneurysms and hemorrhagic stroke see: http://www.strokeassociation.org and http://www.snis.org

About Nfocus Neuromedical, Inc.

Nfocus is a neurovascular development, manufacturing and marketing company focused on treating hemorrhagic stroke. Current and future product programs are aimed at rapid treatment of aneurysms and fistulas in the brain. Based in Palo Alto, California, Nfocus is privately held and venture capital backed. See http://www.nfocusneuro.com for further information. Nfocus products will be used by physicians performing less-invasive surgery with endovascular catheters using a technique known as neurointerventional surgery.


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
2. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes
3. Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research
4. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
5. The Hain Celestial Group Announces the Acquisition of MaraNatha(R) and SunSpire(R) Brands
6. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Milestone Scientific Announces Chicago Dental Societys 143rd Midwinter Meeting Proved Successful
9. Zounds Hearing Enters Moorestown and Announces $225,000 Hearing Partnership With Twilight Wish Foundation
10. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
11. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: